Breaking News

QPharma Appoints DEA Director

By Kristin Brooks | March 19, 2014

Crusan brings extensive compliance experience

Matt Crusan has been appointed director of DEA Compliance and Services at QPharma. Mr. Crusan has served as a diversion investigator with the Drug Enforcement Administration (DEA), and brings extensive knowledge of DEA regulatory policy to QPharma’s newly established DEA compliance practice.
 
Mr. Crusan joins the company from the Pharma Compliance Group, where he served as director of regulatory affairs providing DEA compliance consulting services to manufacturers, distributors, hospitals, and retail pharmacy chains. Mr. Crusan also has experience conducting enterprise-wide DEA gap analyses and development of Suspicious Order & Monitoring (SOM) programs for drug wholesalers and manufacturers.
 
The new DEA compliance practice will include offerings including mock DEA audits and inspections, due diligence/diversion analysis, Standard Operating Procedure review, and physician risk analysis.
 
“Matt’s outstanding credentials and breadth of experience speak for themselves,” said QPharma president and chief executive officer Patrick P. Den Boer. “We are pleased to welcome him to our Professional Services team.”

Related Compliance:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision